Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate

Journal of Virology

Volumn 75, Issue 14, 2001, Pages 6700-6704

  Chen, C H ^a   Jin, L ^a   Zhu, C ^a   Holz Smith, S ^a   Matthews, T J ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CHIMPANZEE; GUINEA PIG; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; STRAIN DIFFERENCE;

ANIMALS; ANTIBODIES, VIRAL; GUINEA PIGS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNE SERA; MUTATION; NEUTRALIZATION TESTS; PAN TROGLODYTES; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS;

EID: 0034983844     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.14.6700-6704.2001     Document Type: Article

References (53)

1. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: Role of V3-specific antibodies
2. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF2 recombinant vaccines in uninfected volunteers
3. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1
4. HIV-1 induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR5 co-receptor
5. Immunization with recombinant canarypox vectors expressing membrane-anchored gp120 followed by soluble gp160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
6. The antibody response in HIV-1 infection
7. A molecular clasp in the HIV-1 TM protein determines the anti-HIV activity of gp41 derivatives: Implications for viral fusion
8. Characterization of a highly potent neutralizing antiserum against a primary HIV-1 isolate elicited in a virus-infected chimpanzee
9. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection
10. Jitters jeopardize AIDS vaccine trials
11. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D
12. Evaluation of monoclonal antibodies to HIV-1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials
13. Identification and characterization of a neutralization site within the second variable region of HIV-1 gp120
14. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades
15. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross reactivity
16. Human antibody response to a strain specific HIV-1 gp120 epitope associated with cell fusion inhibition
17. HIV-1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees
18. Analysis of intercurrent human immunodeficiency virus infection in phase I and phase II trials of candidate vaccines
19. Conformational epitope on gp120 important in CD4 binding and HIV-1 neutralization identified by a human monoclonal antibody
20. HIV type 1 envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors
21. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in HIV-1 infected humans
22. Detection of replication competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene
23. Induction of antibodies in Guinea pigs and Rhesus monkeys against the human immunodeficiency virus type 1 envelope: Neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains
24. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
25. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development
26. Characterization of neutralizing antibodies to linear and conformational dependent epitopes within the first and second variable regions of HIV-1 gp120
27. Specificity and function of the individual amino acids of an important determinant of HIV-1 that induces neutralizing activity
28. V3 specific neutralizing antibodies in sera from HIV gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120
29. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 of HIV-1 are highly prevalent in the sera of infected humans
30. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies
31. Antibody cross competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein
32. Type-specific neutralization of the HIV with antibodies to env-encoded synthetic peptides
33. A potent neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North America and Africa virus isolates
34. Antibody neutralization of HIV-1
35. HTLVIII/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope
36. Prospect for prevention of human immunodeficiency virus: Purified 120 kDa glycoprotein induces neutralizing antibodies
37. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro
38. Antibodies that inhibit fusion of HIV-infected cells bind a 24-amino acid sequence of the viral envelope, gp120
39. Humoral immune response to the entire HIV envelope glycoprotein made in insect cells
40. Epitopes exposure on functional oligomeric gp41 molecules
41. The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain
42. Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo
43. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptor determined by individual amino acids within the envelope V3 loop
44. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1
45. Neutralization of divergent HIV-1 isolates by conformation dependent human antibodies to gp120
46. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell-line-passaged human immunodeficiency virus type 1 isolates
47. Effect of amino acid changes in the V1/V2 region of HIV-1 gp120 glycoprotein on subunit association, syncytium formation, and neutralization by a neutralizing antibody
48. Discontinuous conserved neutralization epitopes overlapping the CD4-binding region of HIV-1 gp120 envelope glycoprotein
49. Characterization of a discontinuous HIV-1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody
50. CD4-dependent, antibody-sensitive interaction between HIV-1 and its co-receptor CCR5
51. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory adapted isolates of HIV type 1
52. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
53. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies